Table 1.
Demographic and baseline characteristics of the diabetes, CKD, and chronic CVD subgroups (randomized set)
| Diabetes (n=387) | CKD (n=103) | Chronic CVD (n=227) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |
OM 40/ AML 10 mg |
OM 40/ HCTZ 25 mg |
AML 10/ HCTZ 25 mg |
OM 40/ AML 10/ HCTZ 25 mg |
OM 40/ AML 10 mg |
OM 40/ HCTZ 25 mg |
AML 10/ HCTZ 25 mg |
OM 40/ AML 10/ HCTZ 25 mg |
OM 40/ AML 10 mg |
OM 40/ HCTZ 25 mg |
AML 10/ HCTZ 25 mg |
OM 40/ AML 10/ HCTZ 25 mg |
| |
(n=100) |
(n=99) |
(n=92) |
(n=96) |
(n=29) |
(n=25) |
(n=29) |
(n=20) |
(n=56) |
(n=61) |
(n=55) |
(n=55) |
| Age, mean (SD), yrs |
59.7 (8.9) |
60.3 (8.7) |
56.5 (9.4) |
58.1 (9.4) |
71.0 (7.8) |
71.5 (9.4) |
69.4 (9.5) |
68.1 (10.0) |
60.2 (11.2) |
61.1 (9.8) |
58.2 (11.0) |
58.6 (10.9) |
| Male, n (%) |
60 (60.0) |
54 (54.5) |
52 (56.5) |
51 (53.1) |
9 (31.0) |
10 (40.0) |
10 (34.5) |
5 (25.0) |
40 (71.4) |
38 (62.3) |
34 (61.8) |
39 (70.9) |
| Ethnicity |
|
|||||||||||
| Hispanic/Latino, n (%) |
21 (21.0) |
18 (18.2) |
13 (14.1) |
15 (15.6) |
1 (3.4) |
2 (8.0) |
3 (10.3) |
2 (10.0) |
8 (14.3) |
5 (8.2) |
7 (12.7) |
8 (14.5) |
| Race |
|
|||||||||||
| White, n (%) |
72 (72.0) |
73 (73.7) |
58 (63.0) |
67 (69.8) |
18 (62.1) |
19 (76.0) |
21 (72.4) |
13 (65.0) |
40 (71.4) |
45 (73.8) |
37 (67.3) |
35 (63.6) |
| Black, n (%) |
26 (26.0) |
24 (24.2) |
29 (31.5) |
25 (26.0) |
9 (31.0) |
5 (20.0) |
7 (24.1) |
6 (30.0) |
16 (28.6) |
16 (26.2) |
18 (32.7) |
17 (30.9) |
| Obesity, n (%)* |
77 (77.0) |
74 (74.7) |
71 (77.2) |
73 (76.0) |
9 (31.0) |
2 (8.0) |
7 (24.1) |
6 (30.0) |
32 (57.1) |
40 (65.6) |
35 (63.6) |
33 (60.0) |
| Hypertension duration, mean (SD), y |
12.8 (9.6) |
13.2 (10.5) |
11.2 (9.6) |
10.7 (9.8) |
12.1 (8.0) |
14.0 (10.0) |
13.0 (9.3) |
14.8 (14.4) |
12.0 (8.0) |
15.0 (12.3) |
12.9 (9.9) |
13.3 (11.0) |
| Baseline BP, mean (SD), mm Hg | 172.2/98.6 (13.5/7.5) | 173.1/97.8 (14.7/7.6) | 170.7/99.3 (13.6/6.7) | 170.7/98.3 (16.0/6.9) | 174.4/96.4 (12.5/8.8) | 172.2/96.0 (11.6/7.6) | 172.9/97.4 (17.1/6.6) | 173.8/96.6 (16.5/6.5) | 173.4/101.0 (16.2/10.6) | 172.8/99.3 (11.7/9.3) | 174.2/100.8 (16.7/7.1) | 171.7/100.4 (11.0/9.1) |
*BMI ≥30 kg/m2.
AML, amlodipine; BMI, body mass index; CKD, chronic kidney disease; CVD, cardiovascular disease; HCTZ, hydrochlorothiazide; OM, olmesartan medoxomil; SD, standard deviation.